U.S. markets close in 6 hours 27 minutes

EyeGate Pharmaceuticals, Inc. (EYEG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8138-0.0862 (-2.97%)
As of 9:33AM EDT. Market open.

EyeGate Pharmaceuticals, Inc.

271 Waverley Oaks Road
Suite 108
Waltham, MA 02452
United States
781 788 8869
http://www.eyegatepharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephen FromExec. Chairman560kN/A1963
Ms. Sarah RomanoChief Financial Officer324.36kN/A1980
Dr. Brian M. Strem Ph.D.Pres, CEO & DirectorN/AN/A1979
Dr. Franz Obermayr Ph.D.Exec. VP of Clinical Devel.N/AN/A1969
Dr. MaryJane RafiiConsultantN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

Corporate Governance

EyeGate Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.